Other
Foundation for Sarcoidosis Research
Total Trials
6
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 6 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed trials have results
Key Signals
2 recruiting1 with results
Enrollment Performance
Analytics
Phase 2
1(50.0%)
Phase 1
1(50.0%)
2Total
Phase 2(1)
Phase 1(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (6)
Showing 6 of 6 trials
NCT07159074Phase 2Recruiting
Repurposing Tilmanocept for Cardiac Sarcoidosis
Role: collaborator
NCT06234384Recruiting
Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)
Role: lead
NCT03902223Completed
Routine Cardiac Screening in Sarcoidosis Patients
Role: lead
NCT03824392Phase 1Completed
Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis
Role: collaborator
NCT05089565Completed
Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis
Role: collaborator
NCT04342403Unknown
Patient Reported Outcome Instruments in Sarcoidosis
Role: collaborator
All 6 trials loaded